相关实验视频
Updated: Jun 19, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
用肉毒神经毒素治疗帕金森病的治疗方法
Wolfgang H Jost1, Emir Berberovic2
1Parkinson-Klinik Ortenau, Kreuzbergstraße 12-16, 77709, Wolfach, Germany. w.jost@parkinson-klinik.de.
Journal of neural transmission (Vienna, Austria : 1996)
|July 25, 2024
概括
肉毒神经毒素 (BoNT) 为帕金森病症状提供了有效的治疗方法. 本综述详细介绍了BoNT的应用,副作用和批准,用于管理帕金森病的运动和非运动问题.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 肉毒神经毒素 (BoNT) 自20世纪70年代以来一直在使用.
- BoNT的功能是通过抑制神经肌肉结点和细胞的乙胆释放来起作用.
- 它越来越多地用于管理帕金森病的症状.
研究的目的:
- 审查BoNT在帕金森病治疗中的治疗应用.
- 概述帕金森病中BoNT疗法的指示,副作用和监管批准.
- 讨论BoNT在治疗初级和二级帕金森病症状中的作用.
主要方法:
- 关于肉毒神经毒素和帕金森病的研究文献综述.
- 对有关疗效和安全的临床数据的分析.
- 对帕金森病治疗中BoNT的监管批准进行审查.
主要成果:
- 对于帕金森病的特定运动和非运动症状,BoNT是有效的.
- 对于某些症状,BoNT是主要的治疗;对于其他人来说,这是次要的选择.
- 越来越多的证据支持在帕金森病管理中扩大BoNT的使用.
结论:
- 肉毒神经毒素是帕金森病的有价值的治疗选择.
- 了解其指示,副作用和批准对于最佳的患者护理至关重要.
- 进一步的研究可能会发现BoNT在神经疾病中的其他应用.
相关概念视频
Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
Parkinson's Disease: Overview
512
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
512
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
664
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
664
Skeletal Muscle Relaxants: Therapeutic Uses
478
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
478
Anticholinesterase Agents: Poisoning and Treatment
833
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
833
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K

